Novartis Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Novartis wird ein jährliches Gewinn- und Umsatzwachstum von 7% bzw. 2.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 37% betragen.

Wichtige Informationen

7.0%

Wachstumsrate der Gewinne

9.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	2.2%
Zukünftige Eigenkapitalrendite	37.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NYSE:NVS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	53,242	13,195	16,857	19,530	14
12/31/2025	52,663	12,472	16,067	18,507	17
12/31/2024	50,479	10,989	14,775	16,979	15
9/30/2024	49,940	11,761	12,552	15,973	N/A
6/30/2024	48,860	10,083	13,560	15,065	N/A
3/31/2024	47,733	9,107	12,071	13,766	N/A
12/31/2023	46,660	8,568	13,660	14,458	N/A
9/30/2023	45,850	7,245	15,507	16,022	N/A
6/30/2023	44,541	7,062	13,241	15,365	N/A
3/31/2023	41,694	5,976	14,009	15,544	N/A
12/31/2022	43,461	6,049	12,167	14,236	N/A
9/30/2022	46,017	21,042	11,545	14,009	N/A
6/30/2022	48,601	22,472	11,714	14,213	N/A
3/31/2022	52,997	24,184	12,349	14,590	N/A
12/31/2021	43,974	22,908	13,201	15,071	N/A
9/30/2021	52,385	9,807	13,015	15,192	N/A
6/30/2021	51,556	8,984	11,222	13,423	N/A
3/31/2021	49,884	7,955	10,699	13,252	N/A
12/31/2020	49,898	8,072	11,445	13,650	N/A
9/30/2020	49,584	7,103	11,743	13,185	N/A
6/30/2020	49,528	7,210	13,255	14,591	N/A
3/31/2020	49,930	7,451	13,077	14,240	N/A
12/31/2019	48,677	7,142	12,341	13,625	N/A
9/30/2019	47,858	7,238	12,122	13,851	N/A
6/30/2019	46,762	7,077	11,477	13,339	N/A
3/31/2019	46,391	12,697	11,778	13,671	N/A
12/31/2018	46,099	12,797	12,447	14,272	N/A
9/30/2018	47,366	13,552	11,748	13,914	N/A
6/30/2018	48,672	13,752	N/A	13,450	N/A
3/31/2018	49,513	8,004	N/A	13,090	N/A
12/31/2017	43,404	7,499	N/A	12,621	N/A
9/30/2017	49,527	6,684	N/A	12,804	N/A
6/30/2017	49,176	6,543	N/A	12,449	N/A
3/31/2017	49,361	6,367	N/A	11,978	N/A
12/31/2016	49,386	6,712	N/A	11,475	N/A
9/30/2016	49,606	6,807	N/A	12,041	N/A
6/30/2016	49,750	6,672	N/A	11,936	N/A
3/31/2016	49,967	6,722	N/A	11,735	N/A
12/31/2015	50,387	7,017	N/A	11,897	N/A
9/30/2015	50,635	8,417	N/A	12,945	N/A
6/30/2015	51,450	9,697	N/A	13,830	N/A
3/31/2015	52,503	10,536	N/A	14,260	N/A
12/31/2014	53,634	10,657	N/A	13,897	N/A
9/30/2014	53,908	10,191	N/A	13,142	N/A
6/30/2014	53,514	9,233	N/A	13,510	N/A
3/31/2014	52,845	9,095	N/A	12,687	N/A
12/31/2013	52,716	9,192	N/A	13,174	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NVSDas prognostizierte Gewinnwachstum (7% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: NVSDie Erträge des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).

Hohe Wachstumserträge: NVSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: NVSDie Einnahmen des Unternehmens (2.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: NVSDie Einnahmen des Unternehmens (2.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NVSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (37%)

Novartis Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Recent updates

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

What To Expect When Novartis Reports Q3 2024 Results

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Why Novartis Deserves Your Attention After Q2 2024 Results

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis: Buy This Blue-Chip Dividend Stock On Sale Now

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis Looks To Get Back On Track With Q1 Earnings

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

New And Improved Novartis

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis: Better Margin Visibility Ex-Sandoz

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis: Buy This Dividend Aristocrat For Consistent Income

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken